Mark DeBenedette

3.0k total citations
37 papers, 2.3k citations indexed

About

Mark DeBenedette is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Mark DeBenedette has authored 37 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Immunology, 13 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Mark DeBenedette's work include Immunotherapy and Immune Responses (20 papers), Immune Cell Function and Interaction (13 papers) and T-cell and B-cell Immunology (12 papers). Mark DeBenedette is often cited by papers focused on Immunotherapy and Immune Responses (20 papers), Immune Cell Function and Interaction (13 papers) and T-cell and B-cell Immunology (12 papers). Mark DeBenedette collaborates with scholars based in United States, Canada and Germany. Mark DeBenedette's co-authors include Tania H. Watts, Tak W. Mak, Arda Shahinian, Jennifer L. Cannons, Charles A. Nicolette, Brian H. Barber, Irina Y. Tcherepanova, Ko Okumura, Hideo Yagita∥ and Nina Chu and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Mark DeBenedette

37 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark DeBenedette United States 22 1.8k 680 490 182 162 37 2.3k
Patricia J. Noel United States 12 2.1k 1.1× 637 0.9× 428 0.9× 162 0.9× 204 1.3× 14 2.5k
Florry A. Vyth‐Dreese Netherlands 25 2.1k 1.2× 973 1.4× 633 1.3× 130 0.7× 254 1.6× 53 2.9k
Nadège Bercovici France 27 1.8k 1.0× 1.1k 1.6× 612 1.2× 137 0.8× 134 0.8× 42 2.5k
Charles A. Nicolette United States 24 871 0.5× 579 0.9× 1.3k 2.6× 155 0.9× 216 1.3× 51 2.1k
Janet E. Buhlmann United States 13 1.4k 0.8× 473 0.7× 342 0.7× 130 0.7× 144 0.9× 21 2.0k
Belinda Palermo Italy 20 1.4k 0.8× 705 1.0× 304 0.6× 90 0.5× 73 0.5× 42 1.9k
Michael Probst‐Kepper Germany 21 1.4k 0.8× 701 1.0× 727 1.5× 81 0.4× 114 0.7× 32 2.0k
Juan Dubrot Spain 25 1.4k 0.8× 841 1.2× 525 1.1× 100 0.5× 153 0.9× 45 2.1k
Naofumi Takemoto Japan 14 2.3k 1.2× 767 1.1× 698 1.4× 172 0.9× 122 0.8× 17 3.1k
G J Freeman United States 21 1.9k 1.1× 485 0.7× 443 0.9× 104 0.6× 218 1.3× 25 2.6k

Countries citing papers authored by Mark DeBenedette

Since Specialization
Citations

This map shows the geographic impact of Mark DeBenedette's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark DeBenedette with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark DeBenedette more than expected).

Fields of papers citing papers by Mark DeBenedette

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark DeBenedette. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark DeBenedette. The network helps show where Mark DeBenedette may publish in the future.

Co-authorship network of co-authors of Mark DeBenedette

This figure shows the co-authorship network connecting the top 25 collaborators of Mark DeBenedette. A scholar is included among the top collaborators of Mark DeBenedette based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark DeBenedette. Mark DeBenedette is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
DeBenedette, Mark, et al.. (2023). A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma. Human Vaccines & Immunotherapeutics. 19(2). 2220629–2220629. 4 indexed citations
2.
3.
Figlin, Robert A., Nizar M. Tannir, Robert G. Uzzo, et al.. (2020). Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 26(10). 2327–2336. 53 indexed citations
4.
Gay, Cynthia L., Mark DeBenedette, Irina Y. Tcherepanova, et al.. (2017). Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection. AIDS Research and Human Retroviruses. 34(1). 111–122. 50 indexed citations
5.
Amin, Asim, Arkadiusz Z. Dudek, Theodore F. Logan, et al.. (2015). Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. Journal for ImmunoTherapy of Cancer. 3(1). 14–14. 152 indexed citations
6.
Nicolette, Charles A., Mark DeBenedette, Irina Y. Tcherepanova, et al.. (2014). Soluble CD83 ameliorates experimental colitis in mice. Mucosal Immunology. 7(4). 1006–1018. 38 indexed citations
7.
Jenabian, Mohammad-Ali, Charles A. Nicolette, Irina Y. Tcherepanova, et al.. (2013). Impact of Autologous Dendritic Cell–Based Immunotherapy (AGS-004) on B- and T-Cell Subset Changes and Immune Activation in HIV-Infected Patients Receiving Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 64(4). 345–350. 2 indexed citations
8.
Raney, Alexa, et al.. (2013). Evaluation of RNA Amplification Methods to Improve DC Immunotherapy Antigen Presentation and Immune Response. Molecular Therapy — Nucleic Acids. 2. e91–e91. 6 indexed citations
9.
Ge, Wei, Jacqueline Arp, Jifu Jiang, et al.. (2010). Induction of Kidney Allograft Tolerance by Soluble CD83 Associated With Prevalence of Tolerogenic Dendritic Cells and Indoleamine 2,3-Dioxygenase. Transplantation. 90(12). 1286–1293. 51 indexed citations
10.
DeBenedette, Mark, David M. Calderhead, Irina Y. Tcherepanova, Charles A. Nicolette, & Don Healey. (2010). Potency of Mature CD40L RNA Electroporated Dendritic Cells Correlates With IL-12 Secretion by Tracking Multifunctional CD8+/CD28+ Cytotoxic T-cell Responses In Vitro. Journal of Immunotherapy. 34(1). 45–57. 32 indexed citations
11.
Lian, Dameng, Weihua Liu, Jacqueline Arp, et al.. (2010). Prevention of Chronic Renal Allograft Rejection by Soluble CD83. Transplantation. 90(12). 1278–1285. 37 indexed citations
12.
13.
14.
Shi, Yonghong, Jelena Tomić, David Cervi, et al.. (2004). Effect of Serum and Antioxidants on the Immunogenicity of Protein Kinase C-Activated Chronic Lymphocytic Leukemia Cells. Journal of Immunotherapy. 28(1). 28–39. 19 indexed citations
15.
Cannons, Jennifer L., et al.. (2001). 4-1BB Ligand Induces Cell Division, Sustains Survival, and Enhances Effector Function of CD4 and CD8 T Cells with Similar Efficacy. The Journal of Immunology. 167(3). 1313–1324. 296 indexed citations
16.
DeBenedette, Mark, Tao Wen, Martin F. Bachmann, et al.. (1999). Analysis of 4-1BB Ligand (4-1BBL)-Deficient Mice and of Mice Lacking Both 4-1BBL and CD28 Reveals a Role for 4-1BBL in Skin Allograft Rejection and in the Cytotoxic T Cell Response to Influenza Virus. The Journal of Immunology. 163(9). 4833–4841. 235 indexed citations
17.
DeBenedette, Mark, Arda Shahinian, Tak W. Mak, & Tania H. Watts. (1997). Costimulation of CD28- T lymphocytes by 4-1BB ligand. The Journal of Immunology. 158(2). 551–559. 276 indexed citations
18.
19.
DeBenedette, Mark, Nina Chu, Karen E. Pollok, et al.. (1995). Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP.. The Journal of Experimental Medicine. 181(3). 985–992. 145 indexed citations
20.
Snow, E Charles, Mark DeBenedette, & Karen E. Pollok. (1990). Delivery of the major growth stimulus to resting B cells. Research in Immunology. 141(4). 408–412. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patricia J. Noel Breakdown of academic impact, for papers by Florry A. Vyth‐Dreese Breakdown of academic impact, for papers by Nadège Bercovici Breakdown of academic impact, for papers by Charles A. Nicolette Breakdown of academic impact, for papers by Janet E. Buhlmann Breakdown of academic impact, for papers by Belinda Palermo Breakdown of academic impact, for papers by Michael Probst‐Kepper Breakdown of academic impact, for papers by Juan Dubrot Breakdown of academic impact, for papers by Naofumi Takemoto Breakdown of academic impact, for papers by G J Freeman
Rankless by CCL
2026